Registry for Systemic Eczema Treatments

Last updated: January 13, 2025
Sponsor: Johns Hopkins University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Atopic Dermatitis

Skin Infections/disorders

Rash

Treatment

N/A

Clinical Study ID

NCT06136767
IRB00372852
  • Ages 1-26
  • All Genders

Study Summary

The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Age <26 years old

  • Current physician diagnosis of atopic dermatitis

  • Provide signed informed consent if ≥ 18 years old

  • Provide signed informed consent by parent or legal guardian (if <18 years old) andinformed assent if applicable

  • Subject and/or parent/legal guardian is willing to be contacted in the future bystudy staff

  • Seen for clinical care at Johns Hopkins since 1/1/2017

  • Previously on, currently on, or planning to initiate (within next 6 months) asystemic AD therapy

Exclusion

Exclusion criteria:

  • Age ≥26 years old at the time of registry enrollment

  • Does not speak English

  • If <18 years old, has a primary caretaker who does not speak English

  • If <18 years old, parent/legal guardian is unwilling to sign the written informedconsent

  • Is a foster child

  • Has not received clinical care at Johns Hopkins since 1/1/2017

Study Design

Total Participants: 400
Study Start date:
January 17, 2024
Estimated Completion Date:
December 31, 2026

Study Description

The purpose of the Registry for Systemic Eczema Therapies (RESET) registry is to serve as a database and biospecimen repository of patients with pediatric-onset atopic dermatitis (AD), also known as eczema. This registry seeks to enroll patients with AD who have used or will initiate any systemic treatment(s) for AD. Such a registry will allow investigators to identify patients who are potentially eligible for AD research protocols, including observational studies or clinical trials. The registry will also prospectively collect data that would then serve as a resource for studying a variety of questions surrounding systemic therapy use in patients with AD, for example comparing the effectiveness of treatments or examining treatment effects on patient-reported outcomes. Moreover, the registry would permit safety monitoring of systemic AD medications, as it would include both patients receiving traditional systemic agents with well-known side effect profiles and patients receiving more novel systemic agents with under-characterized side effect profiles. Finally, this registry would allow for the identification of patients with moderate-to-severe AD who may be eligible to receive and benefit from the rapidly expanding number of U.S. Food and Drug Administration (FDA)-approved systemic therapies for AD.

Connect with a study center

  • Johns Hopkins University

    Baltimore, Maryland 21218
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.